Dipyridamole‐induced headache and lower recurrence risk in secondary prevention of ischaemic stroke: a post hoc analysis
Open Access
- 8 July 2014
- journal article
- Published by Wiley in European Journal of Neurology
- Vol. 21 (10) , 1311-1317
Abstract
Background and purpose: Our objective was to investigate the association between recurrent stroke risk and headache induced by extended‐release dipyridamole (ER‐DP) when administered alone or with low‐dose aspirin (ASA+ER‐DP).Methods: This was a post hoc analysis of prospectively collected data on recurrent stroke risk and headache as an adverse event or reason for treatment discontinuation from the PRoFESS (N = 20 332) and ESPS2 (N = 6602) trials. Hazard ratios (HRs) for recurrent stroke were calculated using the Cox model.Results: In PRoFESS, the 2.5‐year recurrent stroke risk in patients receiving ASA+ER‐DP was 8.2% in those with headache within 7 days of starting treatment and 9.4% in those without [HR 0.85, 95% confidence interval (CI) 0.73–0.98; P = 0.03]. Recurrent stroke risk was 5.0% in patients who discontinued ASA+ER‐DP due to headache by day 90 versus 9.2% in those who did not (HR 0.52, 95% CI 0.35–0.77; P = 0.001). No such difference was observed in clopidogrel‐treated patients. In ESPS2, risk of recurrent stroke was 6.2% in patients who discontinued ASA+ER‐DP due to headache by day 90 versus 9.8% in patients who did not (HR 0.62, 95% CI 0.31–1.27; P = 0.19) and 7.3% in patients who discontinued ER‐DP due to headache by day 90 versus 13.2% in those who did not (HR 0.53, 95% CI 0.27–1.04; P = 0.06).Conclusions: Patients taking ASA+ER‐DP in PRoFESS who developed headache had significantly reduced stroke recurrence risk versus those without headache. Similar (non‐significant) findings for ASA+ER‐DP and ER‐DP in ESPS2 suggest that dipyridamole‐induced headache may reflect better cerebrovascular function.Keywords
Funding Information
- Boehringer Ingelheim
This publication has 21 references indexed in Scilit:
- Evidence for a vascular factor in migraineAnnals of Neurology, 2010
- Amelioration of Inflammation and Cytotoxicity by Dipyridamole in Brain Endothelial CellsCerebrovascular Diseases, 2010
- The role of nitric oxide (NO) in migraine, tension-type headache and cluster headachePharmacology & Therapeutics, 2008
- Aspirin and Extended-Release Dipyridamole versus Clopidogrel for Recurrent StrokeNew England Journal of Medicine, 2008
- Translational Therapeutics of DipyridamoleArteriosclerosis, Thrombosis, and Vascular Biology, 2008
- Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trialThe Lancet, 2006
- The Effect of Dipyridamole on Vascular Cell-Derived Reactive Oxygen SpeciesThe Journal of Pharmacology and Experimental Therapeutics, 2005
- Role of Adenosine and Nitric Oxide on the Mechanisms of Action of DipyridamoleStroke, 2005
- The Effect of Circulating Adenosine on Cerebral Haemodynamics and Headache Generation in Healthy SubjectsCephalalgia, 2005
- Migraine pain associated with middle cerebral artery dilatation: reversal by sumatriptanThe Lancet, 1991